Lansoprazole tablets recalled nationwide due to failed dissolution specifications
Dr. Reddy's Laboratories is recalling Lansoprazole 15-mg delayed-release tablets nationwide due to failed dissolution specifications. The tablets may not dissolve properly, potentially affecting medication effectiveness.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves a manufacturing defect where tablets fail to meet dissolution specifications. No illnesses or hospitalizations have been reported. The defect presents a risk of reduced therapeutic effectiveness.
Plain-English summary
Dr. Reddy's Laboratories is recalling Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg, nationwide in the United States. The recall affects 2,892 cartons with Lot T2100514 and expiration date of January 2023. Lansoprazole is a proton pump inhibitor that inhibits gastric acid secretion.
The FDA classified this as a Class II recall due to failed dissolution specifications. The tablets do not dissolve properly, which may affect how the medication functions in the body.
Consumers who have received this medication should check their medication bottle. If you possess Lansoprazole from Lot T2100514 expiring 01/2023 distributed by Dr. Reddy's Laboratories, contact your pharmacist or healthcare provider for guidance.
Do not stop taking your medication without consulting your healthcare provider. Contact your pharmacist or doctor for further instructions regarding this recall.
The recalled product
- Product
- LANSOPRAZOLE (LANSOPRAZOLE)
- Brand
- LANSOPRAZOLE
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug — Proton Pump Inhibitor
- Hazard
- dissolution-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot T2100514
- Exp 01/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LANSOPRAZOLE
- High
- HighLansoprazole Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2022-05-11
- HighLansoprazole Capsules Recalled for Failed Dissolution in Stability Testing
FDA (Drugs) · 2022-04-06
- ModerateLansoprazole Delayed-Release Capsules Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-04-06
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27